For patients with chronic sinusitis and nasal polyps, nasal endoscopic surgery can remove polyps in a shorter time, with less ...

Research and development expenses were $25.8 million for the quarter ended March 31, 2025, compared to $11.7 million for the ...

Topical deep delivery of corticosteroids into the sinonasal cavity improves symptoms and sleep in patients with chronic rhinosinusitis.

Chronic rhinosinusitis with nasal polyps (CRSwNP) inflammatory endotypes are associated with long-term air pollutant and allergen exposure.

USA: In a recent exposure-matched study, researchers found that long-term exposure to fine particulate matter (PM2.5) may ...

Discover the reasons behind recurring nosebleeds beyond dry air, including medication effects, clotting disorders, structural ...

Pregnant patients with T2IDs using dupilumab did not have an increased rate of adverse events when compared with patients not receiving dupilumab.

AstraZeneca has failed in its bid to get US approval for its IL-5 inhibitor Fasenra as a treatment for chronic rhinosinusitis in people with nasal polyps, after the FDA rejected its marketing ...

On the FDA’s docket this month are two expansion bids, one for GSK’s asthma drug Nucala into COPD and another for Merck’s ...

Sanofi and Regeneron's fast-growing immunology drug Dupixent is on course for a third indication in Europe after being recommended for approval as a treatment for people with nasal polyps.

World Asthma Day, observed annually on the second Tuesday of May, aims to raise awareness about this chronic respiratory ...

Shares of Regeneron Pharmaceuticals are trading higher Wednesday recovering after a drop on Tuesday that followed the release ...